Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK9 | P45984 | 10/20 | 1.00 |
| ▸ | MAPK8 | P45983 | 8/20 | 1.00 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.70 |
| ▸ | CDK2 | P24941 | 7/20 | 0.63 |
| ▸ | MAPK10 | P53779 | 6/20 | 0.63 |
| ▸ | JUN | P05412 | 1/20 | 0.63 |
| ▸ | IGF1R | P08069 | 2/20 | 0.54 |
| ▸ | CDK1 | P06493 | 2/20 | 0.50 |
| ▸ | CDK4 | P11802 | 2/20 | 0.50 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.50 |
| ▸ | CCND1 | P24385 | 1/20 | 0.50 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.50 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL183113 | 1.00 | MAPK9 (1.00) | MAPK9MAPK8IRAK4CDK2MAPK10 | |
| SCHEMBL183898 | 0.84 | MAPK8 (1.00) | MAPK9MAPK8IRAK4CDK2MAPK10 | |
| SCHEMBL7888011 | 0.84 | MAPK8 (1.00) | MAPK9MAPK8IRAK4CDK2MAPK10 | |
| SCHEMBL6039664 | 0.83 | MAPK9 (0.72) | MAPK9MAPK8IRAK4CDK2MAPK10 | |
| SCHEMBL31500989 | 0.82 | MAPK8 (0.70) | MAPK9MAPK8IRAK4CDK2MAPK10 | |
| SCHEMBL22228781 | 0.82 | MAPK8 (0.70) | MAPK9MAPK8IRAK4CDK2MAPK10 | |
| SCHEMBL22228780 | 0.82 | MAPK8 (0.70) | MAPK9MAPK8IRAK4CDK2MAPK10 | |
| SCHEMBL18427775 | 0.82 | IRAK4 (1.00) | MAPK9MAPK8IRAK4CDK2MAPK10 | |
| SCHEMBL7887171 | 0.81 | MAPK9 (1.00) | MAPK9MAPK8IRAK4CDK2MAPK10 | |
| SCHEMBL15344630 | 0.81 | MAPK9 (1.00) | MAPK9MAPK8IRAK4CDK2MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2401274-B1 | IMIDAZO[1,2-A]PYRIDINES AS JNK MODULATORS | HOFFMANN LA ROCHE (CH) | 2014-10-22 | — | — | EP | disclosed |
| US-8569306-B2 | JNK modulators | HOFFMANN-LA ROCHE, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-8569306-B2 | JNK modulators | HOFFMANN-LA ROCHE, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-20110306618-A1 | JNK Modulators | BUETTELMANN BERND (DE) | 2011-12-15 | — | — | US | disclosed |
| US-20110306618-A1 | JNK Modulators | BUETTELMANN BERND (DE) | 2011-12-15 | — | — | US | disclosed |
| WO-2010097335-A1 | IMIDAZO [1, 2 -A] PYRIDINES AS JNK MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306618-A1 | JNK Modulators | MAPK3, MAPK1, MAPK4 | MAPK9 15/4885MAPK8 11/4885IRAK4 1050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.